Fenaris focuses on regulatory-driven clinical strategy rather than isolated study execution. We work closely with CRO partners and clinical sites to ensure that study design, endpoints, and data generation are directly aligned with conformity assessment requirements and Notified Body expectations. This approach is particularly critical under EU MDR, where insufficient or misaligned clinical evidence remains one of the most common causes of certification delays. 

We have strong expertise in supporting non-EU, especially Asian, manufacturers, where existing clinical data often requires adaptation to meet European methodological and ethical standards. Fenaris provides targeted guidance on evidence bridging, supplemental investigations, and interactions with Competent Authorities and the EMA framework to ensure that clinical programs are both efficient and defensible. Our hospital partners enable rapid site initiation, ethical approvals, and patient recruitment, significantly reducing time to meaningful clinical outcomes. 

By integrating regulatory oversight, CRO coordination, hospital engagement, and authority-facing communication, Fenaris delivers clinical trial assistance that accelerates evidence generation while maintaining full compliance with EU regulatory and ethical requirements. 

Contact Fenaris to initiate a compliant and efficient clinical investigation.